Transforming medicine to develop personalized medicine

"Under the trend of personalized medical treatment, the new drugs in the future will no longer be a" blockbuster "with more than one billion dollars, and personalized research and development for the segmented population will become a trend Translational medicine can bridge the gap between basic research and clinical application, and promote the research and development of personalized drug products " Liu Yuwen, chairman of Suzhou biological nano Park, pointed out Recently, Kaijie (Suzhou) transformation medical center, the first domestic R & D enterprise with transformation medicine as the core, has officially put into operation "Our goal is to move towards products, and we hope to develop products in the next few years, and explore a faster model from transforming medicine to developing application products." Dr Shi Chenyang, President of Asia Pacific region of Kaijie company, said Accelerate personalized drug development Harvard Business Review once pointed out that in the United States, the most commonly used prescription drugs are only effective for less than 60% of patients; research from the University of Hanover in Germany also shows that mismedication has caused a total of 58000 deaths in Germany alone These data show that the practice of "one thousand people and one medicine" is exposing more and more disadvantages "In today's aging society, if we can't make significant improvement in treating people and the right medicine, similar negative effects will surely continue to flood and eventually lead to high medical expenditure." Shi Chenyang pointed out Market research shows that personalized healthcare can save up to $380 billion for the global healthcare market According to the survey and analysis of PWC, the market value of personalized therapy related industries in the United States is up to $232 billion, with an annual growth rate of about 11%, and it is expected to reach $450 billion by 2015 Due to its high economic and social benefits, personalized medicine and drug use have become a hot spot and development trend in the field of biomedicine, and are widely concerned by pharmaceutical enterprises "In addition, in recent years, the output rate of new drug R & D mode relying on high-throughput molecular screening has declined In order to improve the success rate and efficiency of R & D, R & D personnel pay more and more attention to targeted drug R & D Based on clinical needs, and the application of translational medicine in R & D has attracted more and more attention of new drug R & D enterprises and institutions." Shi Chenyang pointed out Translational medicine emphasizes the two-way transformation between laboratory and clinical research The goal is to accelerate the transformation of basic research results to new clinical diagnosis and treatment technology and drug research and development Its core value is to integrate the whole chain from new drug research and development to clinical application By comparing the difference between animal experiment and human clinical research, we can speed up the research and development of new drugs and reduce the risk of new drug development It is understood that although China has made some progress in the field of translational medicine research, it is far from meeting the needs of the market and the public "At present, almost all of the major pharmaceutical companies abroad are engaged in the research and development of drug personalization, but few of the local pharmaceutical companies in China are engaged in the research and development of drug personalization." Liu Yuwen said "This is mainly because there are still some bottlenecks in the development of domestic translational medicine in the field of new drug research and development For example, there are not many pharmaceutical enterprises in China that have the ability to develop new drug research and industrialization according to clinical demands; the case data of competitors in some medical institutions are too conservative to show people; the full-time research doctors and nurses still need to be strengthened " Shi Chenyang further pointed out Commercialized operation transforming medicine In order to actively promote the development of translational medicine and better serve the personalized drug research and development, the joint venture of Kaijie (Suzhou) translational medicine center established by Kaijie and Suzhou biological nano Park was officially put into operation "At present, many translational medicine centers have been set up in China, but they are mainly clinical units and research units This is the first R & D enterprise in China that focuses on the commercialization of translational medicine." Dr Zhang peizhuo, general manager of Kaijie (Suzhou) transformation medical center, said: "the center's business will cover four major fields: biomarkers, genealogy, next generation sequencing (NGS) and pharmacogenomics, providing early technology development and later business operation services for international and local pharmaceutical enterprises in China's new drug research and development projects, and will vigorously promote the discovery and development of biomarkers Validation work, and promote accelerated drug development and commercial application of accompanying diagnostic products for the Chinese market " Shi Chenyang further pointed out that the establishment of the joint venture R & D company is also to explore how to more quickly and more standardized the clinical research into the application of patients and drug research and development, hoping to develop corresponding products in the next few years, and better serve drug research and development " "The trend of personalized healthcare in the future is irresistible, and the establishment of this joint venture is in line with this trend." Liu Yuwen said: "on the other hand, it is also to provide more and better services for new drug research and development of innovative enterprises in the park At present, Kaijie (Suzhou) transformation medical center has signed strategic cooperation agreements with four enterprises in the park, including cobay, Gemma, sensi Zhen and Baituo "